4//SEC Filing
Chesworth Richard 4
Accession 0000899243-21-033638
CIK 0001815442other
Filed
Aug 18, 8:00 PM ET
Accepted
Aug 19, 4:30 PM ET
Size
14.9 KB
Accession
0000899243-21-033638
Insider Transaction Report
Form 4
Chesworth Richard
Chief Scientific Officer
Transactions
- Exercise/Conversion
Stock Option (Right to Buy)
2021-08-17−54,000→ 297,119 totalExercise: $20.00Exp: 2030-08-19→ Common Stock (54,000 underlying) - Sale
Common Stock
2021-08-17$49.90/sh−8,809$439,612→ 45,191 total - Sale
Common Stock
2021-08-17$51.68/sh−2,928$151,325→ 288 total - Exercise/Conversion
Common Stock
2021-08-17$20.00/sh+54,000$1,080,000→ 54,000 total - Sale
Common Stock
2021-08-17$50.37/sh−41,975$2,114,243→ 3,216 total - Sale
Common Stock
2021-08-17$52.09/sh−288$15,002→ 0 total
Footnotes (6)
- [F1]This sale was effected pursuant to a Rule 10b5-1 trading plan adopted on November 6, 2020.
- [F2]The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $49.04 to $50.03. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
- [F3]The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $50.04 to $51.02. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
- [F4]The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $51.05 to $52.00. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
- [F5]The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $52.06 to $52.16. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
- [F6]Twenty-five percent (25%) of the shares subject to this option vested and became exercisable on August 17, 2021, and the remainder of the shares shall vest in equal monthly installments for a period of thirty-six (36) months thereafter.
Documents
Issuer
Kymera Therapeutics, Inc.
CIK 0001815442
Entity typeother
Related Parties
1- filerCIK 0001821188
Filing Metadata
- Form type
- 4
- Filed
- Aug 18, 8:00 PM ET
- Accepted
- Aug 19, 4:30 PM ET
- Size
- 14.9 KB